Werewolf Therapeutics, Inc.

NasdaqGS:HOWL Rapporto sulle azioni

Cap. di mercato: US$92.6m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Werewolf Therapeutics Gestione

Gestione criteri di controllo 3/4

Werewolf Therapeutics' Il CEO è Dan Hicklin, nominato in Oct2017, e ha un mandato di 6.83 anni. la retribuzione annua totale è $ 1.37M, composta da 42.7% di stipendio e 57.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.48% delle azioni della società, per un valore di $ 1.34M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.6 anni e 4.9 anni.

Informazioni chiave

Dan Hicklin

Amministratore delegato

US$1.4m

Compenso totale

Percentuale dello stipendio del CEO42.7%
Mandato del CEO6.9yrs
Proprietà del CEO1.5%
Durata media del management3.7yrs
Durata media del Consiglio di amministrazione5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

Jul 31
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jul 01

Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Jun 04
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 04

Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Feb 07
Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Jan 19
Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Dec 09
There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Sep 30
Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 13
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

May 06
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Jan 27
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

Oct 24
We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Jul 08
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Mar 24
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Dec 09
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dan Hicklin rispetto agli utili di Werewolf Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$54m

Mar 31 2024n/an/a

-US$42m

Dec 31 2023US$1mUS$583k

-US$37m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$2mUS$530k

-US$54m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$62m

Mar 31 2022n/an/a

-US$115m

Dec 31 2021US$2mUS$498k

-US$202m

Sep 30 2021n/an/a

-US$205m

Jun 30 2021n/an/a

-US$197m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$3mUS$425k

-US$28m

Compensazione vs Mercato: La retribuzione totale di Dan ($USD 1.37M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Dan è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Dan Hicklin (60 yo)

6.9yrs

Mandato

US$1,366,904

Compensazione

Dr. Daniel J. Hicklin, Ph D., also known as Dan, Founded Werewolf Therapeutics, Inc. in October 2017 and has been its President and Chief Executive Officer since August 2019. He serves on its Board of Dire...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Daniel Hicklin
Founder6.9yrsUS$1.37m1.48%
$ 1.4m
Timothy Trost
CFO, Treasurer & Assistant Secretary3.6yrsUS$815.59k0%
$ 0
Randi Isaacs
Chief Medical Officer3.8yrsUS$855.77k0%
$ 0
William Winston
Senior Vice President of Researchless than a yearNessun datoNessun dato
Chulani Karunatilake
Chief Technology Officer3.3yrsUS$3.86mNessun dato
Ellen Lubman
Chief Business Officer4.1yrsNessun datoNessun dato

3.7yrs

Durata media

64yo

Età media

Gestione esperta: Il team dirigenziale di HOWL è considerato esperto (durata media dell'incarico 3.6 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Daniel Hicklin
Founder6.9yrsUS$1.37m1.48%
$ 1.4m
Luke Evnin
Independent Chairman of the Board6.9yrsUS$104.03k0%
$ 0
Michael Sherman
Independent Director3.3yrsUS$78.66k0%
$ 0
Charles Craik
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Vijay Kuchroo
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Briggs W. Morrison
Independent Director4.8yrsUS$62.32k0.036%
$ 32.9k
Karl Wittrup
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Michael Atkins
Member of Scientific Advisory Board & Director6.1yrsNessun dato0.033%
$ 30.6k
Alon Lazarus
Independent Director5.1yrsUS$78.53k4.68%
$ 4.3m
Meeta Chatterjee
Independent Director2.9yrsUS$65.36k0%
$ 0
Derek DiRocco
Independent Director3.8yrsUS$72.53k0%
$ 0
Dario Vignali
Member of Scientific Advisory Boardno dataNessun datoNessun dato

5.0yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HOWL sono considerati esperti (durata media dell'incarico 4.9 anni).